- $1.67bn
- $1.43bn
- $62.90m
U.S. STOCKS ON THE MOVE-Cal-Maine, Rivian, Alkermes
Brief: Nuvation Bio Announces Acquisition Of Japan Rights To Safusidenib From Daiichi Sankyo
Nuvation Bio rises after securing Japan rights to brain cancer drug
Nuvation Bio Q4 collaboration and license agreements revenue rises
Brief: Nuvation Bio Q4 EPS USD -0.11
Brief: Nuvation Bio Announces Pivotal Global Phase 3 Sigma Trial (G203) For Safusidenib In Idh1-Mutant Glioma
Brief: Nuvation Bio Reports Preliminary Fourth Quarter And Full Year 2025 Financial Results And Provides 2026 Outlook Ahead Of 44Th Annual J.P. Morgan Healthcare Conference
Brief: Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, Roblox
U.S. STOCKS ON THE MOVE-Microsoft, Wyndham Hotels & Resorts, Daktronics
U.S. STOCKS ON THE MOVE-Wendy's, Bristol Myers Squibb, Macy's
Nuvation Bio rises on brain cancer drug data
U.S. RESEARCH ROUNDUP- Amgen, Crowdstrike, Micron Technology
Nuvation Bio beats Q3 revenue expectations, driven by IBTROZI sales
Brief: Nuvation Bio Q3 EPS USD -0.16
Brief: Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma
Brief: Nuvation Bio To Report Third Quarter 2025 Financial Results And Provide Business Update On November 3, 2025
U.S. RESEARCH ROUNDUP-Electronic Arts, Kala Bio, Semtech
Brief: Japan Approves Nuvation Bio’s IBTROZITM for Advanced ROS1-Positive Non-Small Cell Lung Cancer